The American Journal of Gastrointestinal Endoscopy published a multicenter study on the treatment of gastrointestinal subepithelial tumors led by the Bellvitge Biomedical Research Institute (IDIBELL) and the Digestive Endoscopy Unit of the Bellvitge University Hospital (HUB).
The objective was to select non-invasive biomarkers with diagnostic and prognostic utility, which allow the identification of individuals with a real possibility of recovering sperm from a testicular biopsy, necessary for assisted reproduction treatment.
Small RNAs in semen are useful biomarkers to determine the origin of azoospermia Read More »
This past June 9 and 10, NeuroDebate took place, a conference promoted by the Bellvitge University Hospital (HUB), the Bellvitge Biomedical Research Institute (IDIBELL) and the University of Barcelona.
The Bioheart group has carried out a retrospective analysis of 2,376 heart transplants performed in 14 hospitals throughout the country and has concluded that the choice between peripheral or central cannulation for ECMO-Venoarterial placement determines an improvement in survival.
A new study seeks solutions to minimize complications in heart transplants Read More »
It is the first treatment in the last 30 years that represents a relative improvement of 38% in the overall survival of patients compared to standard treatment. The results of Phase III study ZUMA-7 show that this new treatment with Yescarta (axicabtagén ciloleucel, known as axicel) reduces the risk of death by 27.4%.
A study that reveals that microtubules, apart from their known structural role in cells, they also exert an active influence on neuronal communication.
Depolymerization of microtubules contributes to spontaneous neurotransmitter release Read More »
The Neurological Diseases and Neurogenetics research group of the Bellvitge Biomedical Research Institute (IDIBELL) and the Multiple Sclerosis Unit of the Neurology Service of the HUB have co-organized this day to explain the new advances achieved in the approach and search of the disease and to give voice to patients.
Advances in the approach to multiple sclerosis, within reach of patients on World MS Day Read More »
It is an aptamer, a small nucleic acid molecule that specifically recognizes a receptor highly expressed in tumor cells of breast cancer, sarcoma, melanoma, and colon cancer, among others. The new molecule could be linked to cancer treatments and used as a platform for localized drug delivery that reduces side effects.
The excellent results of the HERMeS clinical trial, a pioneer in the application of telemedicine and mHealth in Heart Failure, have been presented at the Heart Failure 2023 Congress, which took place between May 20 and 23 in Prague (Republic of Czech).
Bellvitge’s mHealth research stood out in the most relevant Congress of Heart Failure Read More »
The IDIBELL, the ICO, the CSIC and the Catalan Banc de Sang i Teixits sign an agreement to investigate CAR-NK cells production, which are easier to generate than the CAR-T cells that are already successfully being used in immunotherapy.
Genetically engineered stem cells to power cancer immunotherapy Read More »
